Biophytis and Asian Investors to Launch Phase 3 Sarcopenia Trial

Biophytis has secured a landmark agreement with a consortium of Asian investors, including Ronghui Renhe Life Technology, to finance and launch the first Phase 3 trial for sarcopenia. The joint venture, valued at $20 million, is set to operate from Hong Kong and will commence clinical operations in 2026. The consortium's investment marks a key step in advancing Biophytis' drug candidate, BIO101, which aims to provide a treatment for this degenerative muscle disease.

The joint venture will leverage Europe's research and innovation with China's development expertise and Hong Kong's financial acumen. It will focus on commercializing BIO101 in China, Japan, and Korea. The Phase 3 trial plans to include 932 patients across Europe and Asia, offering potential hope to millions affected by sarcopenia, a condition currently without approved treatment.